Journal of Molecular Biology
Regular articleGenomic sites of topoisomerase II activity determined by comparing DNA breakage enhanced by three distinct poisons1
Introduction
DNA topoisomerases are essential enzymes that modify the topology of nucleic acids, and can be classified into distinct families based on sequence homology and conserved catalytic mechanism (Wang, 1996). Type II DNA topoisomerases introduce double-stranded breaks into DNA segments, transport a second DNA segment through the cut, and finally reseal cut strands. Biochemical and genetic data demonstrate that DNA topoisomerase II is essential for the segregation of newly replicated pairs of intertwined chromosomes Holm et al 1985, Downes et al 1991, Adachi et al 1991, and is involved in the modulation of the supercoiling state of intracellular DNA (Liu & Wang, 1987). Eukaryotic topoisomerases are targets of very effective antitumor drugs that interfere with the enzyme activity by stabilising a reaction intermediate wherein DNA strands are cut and covalently linked to tyrosine residues of the protein Pommier 1997, Froelich-Ammon and Osheroff 1995, Capranico et al 1997, Wang 1996. The enzyme-poisoning action of natural compounds has been conserved during evolution, most likely because it is a very efficient mechanism of cell killing.
Topoisomerase II is a structural component of the nuclear matrix of interphase cells, is a major component of chromosome scaffolds, and is required for mitotic chromosome condensation (Poljak & Käs, 1995). Moreover, specific DNA helicases likely associate with topoisomerase II for faithful transmission of chromosomes to daughter cells Watt et al 1995, Watt et al 1996. Recently, a multi-protein complex (CHRAC) containing topoisomerase II has been shown to remodel nucleosome arrays and to increase the accessibility of DNA to other protein factors, thus suggesting a role of CHRAC in the unravelling of repressed chromatin domains (Varga-Weisz et al., 1997). Recent reports emphasise the idea that nuclear enzyme molecules may constitute diverse pools of functionally distinct topoisomerase II proteins. The enzyme is distributed widely over interphase chromatin, but is also concentrated in specific regions of heterochromatin (Swedlow et al., 1993). In addition, distinct populations of topoisomerase II have been distinguished by different dynamic patterns in chromosomes (Swedlow et al., 1993).
To achieve a more complete understanding of topoisomerase II functions, much attention has focused on the sites of topoisomerase II activity in the chromatin of living cells. This approach has been made possible by the use of antitumor poisons to increase the level of DNA cleavage Rowe et al 1986, Yang et al 1985, Udvardy et al 1985, Reitman and Felsenfeld 1990, Udvardy and Schedl 1991, Kas and Laemmli 1992, Gromova et al 1995b, Borde and Duguet 1996, Ebert et al 1990, Pommier et al 1992. Topoisomerase II has thus been located at scaffold-attachment regions (SARs) Gasser and Laemmli 1986, Adachi et al 1989, Poljak and Kas 1995 and at domain boundary elements (Udvardy & Schedl, 1993), suggesting a role in chromatin organisation. The size of chromatin loops has also been estimated through the use of topoisomerase II poisons as revealed by the length of DNA fragments released from drug-treated nuclei Gromova et al 1995a, Iarovaia et al 1996. DNA cleavage sites were also found to co-localise with DNase I-hypersensitive sites at gene promoters and to be mainly excluded from gene coding sequences Udvardy et al 1985, Reitman and Felsenfeld 1990, Udvardy and Schedl 1991, Kas and Laemmli 1992.
In this approach topoisomerase II poisons are used as a tool to localise the physiological sites of enzyme activity in chromatin domains. Thus, the molecular mechanism of poison interference with the enzyme is of great importance not only for the development of novel effective anticancer drugs, but also for the full understanding of enzyme functions. The molecular action of poisons is peculiar; these agents likely bind to a protein-DNA interface at the enzyme active site, thus hindering strand religation activity of topoisomerases (Capranico et al., 1997). This view is based on several lines of evidence, including sequence specificity of poison action Pommier et al 1993, Capranico et al 1997, photolabelling of DNA by cross-reactive poison analogs Freudenreich and Kreuzer 1994, Pommier et al 1995, and drug binding data Shen et al 1989, Hertzberg et al 1989, Hertzberg et al 1990. In the case of camptothecin, a topoisomerase I poison, models for the drug receptor have been proposed based on the crystal structures of enzyme-DNA complexes (Redinbo et al., 1998) and molecular modelling analyses (Fan et al., 1998). Camptothecin contacts specific amino acid residues as well as the G·C base-pair at the +1 position of the cleavage site that was previously shown to be required for its activity (Pommier et al., 1993).
A single poison (VM-26, 4′-demethylepipodophillotoxin-9-(4,6-O-thionylidine-β-d-glucopyrano-side) has often been used as a tool to map topoisomerase II activity in chromatin domains by low-resolution agarose gel electrophoresis. Since available data demonstrate that VM-26 maintains in vivo the sequence specificity established in vitro(Borgnetto et al., 1996), these investigations are inherently limited. The use of a single poison can indeed fail to reveal genomic sites of enzyme activity where the poison is inefficient in stimulating cleavage (Borgnetto et al., 1996). Thus, in the present work, we have investigated topoisomerase II-dependent DNA cleavage stimulated by clerocidin, VM-26 and dh-EPI (4′-demethyory-3′-deamino-3′-hydroxy-4′-epi doxorubicin), a potent anthracycline analog, in Drosophila Kc cells. The three poisons have markedly different sequence specificity in vitro requiring a guanine, a cytosine and a 5′-TA dinucleotide, respectively, at the 3′ terminus generated by topoisomerase II Capranico et al 1994, Capranico et al 1997. We have shown that clerocidin, unlike the other poisons, mainly stimulated irreversible DNA cleavage in SV40 DNA (Binaschi et al., 1997), since it likely forms a covalent adduct with the 3′ terminus guanine. The studied genomic regions of Drosophila Kc cells were known to be sites of enzyme activity, and topoisomerase II cleavage sites were in part sequenced in these regions in the case of VM-26 and dh-EPI Kas and Laemmli 1992, Borgnetto et al 1996. Our present findings demonstrate that the use of distinct poisons greatly improves the definition of genomic sites of topoisomerase II activity. Indeed, we present evidence that topoisomerase II may be involved in maintaining diverse chromatin structures at the two genomic loci studied.
Section snippets
Long-range DNA cleavage by topoisomerase II at different genomic loci of D. melanogaster Kc cells
In a previous study, we showed with standard agarose gel electrophoresis that VM-26, but not dh-EPI, stimulated DNA breaks in the satellite III repeats (Borgnetto et al., 1996). To determine long-range DNA fragmentation promoted by topoisomerase II, we analysed DNA cleavage in the Drosophila satellite III and histone gene clusters with clerocidin, VM-26 and dh-EPI, by pulse-field gel elechophoresis (PFGE) and Southern blotting (Figure 1). Bulk DNA fragmentation was similar among the three
Discussion
Here, we have presented a fine map of clerocidin-dependent topoisomerase II DNA cleavage sites in vivo in the region of the H2A and H2B histone genes of D. melanogaster, as well as an analysis of long-range cleavage at two genomic loci with three diverse poisons. The information is relevant to the understanding of the functions of DNA topoisomerase II in proliferating Kc cells, as well as of the activity of antitumor poisons. We show that the use of distinct poisons greatly improves the
Materials and cell line
Clerocidin, VM-26, and dh-EPI were obtained from Leo Pharmaceutical Products Ltd A/S (Ballerup, Denmark), Bristol Italiana (Latina, Italy), and Pharmacia-Upjhon (Milan, Italy), respectively. VM-26 and clerocidin were prepared before use in absolute ethanol, and then diluted in deionised water. Dh-EPI was dissolved in DMSO and then diluted in deionized water.Drosophila topoisomerase II was purchased from USB (Cleveland, OH, USA). T4 polynucleotide kinase and polyacrylamide were purchased from
Acknowledgements
We thank Manlio Palumbo (Padua University, Padua, Italy) for sharing with us experimental results before publication, and Emmanuel Käs (CNRS, Toulouse, France) for interesting discussions during the course of the work.
This work was supported by a grant of the Associazione Italiana per la Ricerca sul Cancro, Milan, Italy (to G.C.).
References (46)
- et al.
Chromosome assembly in vitrotopoisomerase II is required for condensation
Cell
(1991) - et al.
A study of drug-induced topoisomerase II-mediated DNA lesions on episomal chromatin
J. Biol. Chem.
(1989) - et al.
Transient inhibition of histone deacetylation alters the structural and functional imprint at fission yeast centromeres
Cell
(1997) - et al.
Topoisomerase poisonsharnessing the dark side of enzyme mechanism
J. Biol. Chem.
(1995) - et al.
Long-range fragmentation of the eukaryotic genome by exogenous and endogenous nucleases proceeds in a specific fashion via preferential DNA cleavage at matrix attachment sites
J. Biol. Chem.
(1995) - et al.
Irreversible trapping of the DNA-topoisomerase I covalent complex. Affinity labeling of the camptothecin binding site
J. Biol. Chem.
(1990) - et al.
DNA topoisomerase II is required at the time of mitosis in yeast
Cell
(1985) - et al.
Resolving the role of topoisomerase II in chromatin structure and function
Trends Cell Biol.
(1995) - et al.
Mechanism of quinolone inhibition of DNA gyrase. Appearance of unique norfloxacin binding sites in enzyme-DNA complexes
J. Biol. Chem.
(1989) - et al.
Molecular structure of a functional Drosophila centromere
Cell
(1997)
Multiple chromosomal populations of topoisomerase II detected in vivo by time-lapse, three-dimensional wide-field microscopy
Cell
Novel partitioning of DNA cleavage sites for Drosophila topoisomerase II
Cell
Sgs1a eukaryotic homolog of E. coli RecQ that interacts with topoisomerase II in vivo and is required for faithful chromosome segregation
Cell
In vivo mapping of DNA topoisomerase II-specific cleavage sites on SV40 chromatin
Cell
Preferential, cooperative binding of DNA topoisomerase II to scaffold-associated regions
EMBO J.
Irreversible and reversible topoisomerase II DNA cleavage stimulated by clerocidinsequence specificity and structural drug determinants
Cancer Res.
In vivo topoisomerase II cleavage sites in the ribosomal DNA of Physarum polycephalum
Biochemistry
Drug-specific sites of topoisomerase II DNA cleavage in Drosophila chromatinheterogeneous localization and reversibility
Cancer Res.
Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin
Nucl. Acids Res.
Influence of structural modifications at the 3′ and 4′ positions of doxorubicin on the drug ability to trap topoisomerase II and to overcome multidrug resistance
Mol. Pharmacol.
A protein-mediated mechanism for the DNA sequence-specific action of topoisomerase II poisons
Trends Pharmacol. Sci.
Inhibitors of DNA topoisomerase II prevent chromatid separation in mammalian cells but do not prevent exit from mitosis
Proc. Natl Acad. Sci. USA
Topoisomerase II cleavage of herpes simplex virus type 1 DNA in vivo is replication dependent
J. Virol.
Cited by (20)
Dissecting the transcriptional functions of human DNA topoisomerase I by selective inhibitors: Implications for physiological and therapeutic modulation of enzyme activity
2010, Biochimica et Biophysica Acta - Reviews on CancerCitation Excerpt :Known topoisomerase poisons have a sequence-selective activity, namely they stabilize Topoisomerase cleavage complexes at specific sites, and not at all of them, in in vitro assays [22]. Similarly to Top2 poisons [84], Top1 poisons with a different site selectivity may be of interest in the development of Top1 modulators with a genomic selectivity. Thus, it may be of interest that batracylin (Fig. 3) stabilizes the Top1cc at selective DNA sites yielding different cleavage patterns as compared with camptothecin, suggesting that the drug may target Top1 at diverse genomic sites also in living cells [85].
Nucleotide-resolution mapping of topoisomerase-mediated and apoptotic DNA strand scissions at or near an MLL translocation hotspot
2006, American Journal of Human GeneticsCitation Excerpt :ELMPCR is, to our knowledge, the first PCR-based technique used successfully to map in vivo TOP2-mediated DNA cleavage in single-copy genes at single-nucleotide resolution. Previous analyses of drug-induced TOP2 cleavage sites in living cells were based on genomic primer-extension techniques and were restricted to satellite DNA repeats and multicopy genes, because of their intrinsically limited detection capacity.14,52 In principle, ELMPCR should be suitable to map any topoisomerase-mediated strand break, including TOP3-mediated DNA cleavage and meiosis-specific DSBs catalyzed by TOP2-like Spo11 family proteins, which also involve enzyme-linked 5′ ends.2,53
Doxorubicin and two of its analogues are preferential inducers of homologous recombination compared with mutational events in somatic cells of Drosophila melanogaster
2003, Mutation Research - Genetic Toxicology and Environmental MutagenesisSequence-specific interactions of drugs interfering with the topoisomerase-DNA cleavage complex
2002, Biochimica et Biophysica Acta - Molecular Basis of DiseaseInvestigation of the biological mode of action of clerocidin using whole cell assays
2001, Bioorganic and Medicinal ChemistryAnthracyclines as Topoisomerase II poisons: From early studies to new perspectives
2018, International Journal of Molecular Sciences
- 1
Edited by J. Karn